Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related NVS
Novartis Division Alcon Receives FDA Approval for AcrySof®IQ Aspheric IOL with UltraSert Pre-loaded Delivery System
US Stock Futures Up; All Eyes On Jobs Report
4 Pharma Stocks Gaining from High Pricing Power (Zacks)
Related ZIOP
6 U.S.-Listed Stocks Short Sellers Are Strongly Betting Against
The Approaching 'Vast Opportunity' For Intrexon

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

Jul 2015Leerink SwannMaintainsOutperform
Jun 2015Bryan GarnierUpgradesNeutralBuy
Mar 2015NatixisUpgradesNeutralBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (IEX + NVS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters